Cross posted from: https://europe.pub/post/13201474

Check out the amazing Conclusion from the primary source: "Daraxonrasib was associated with treatment-related adverse events of grade 3 or higher in one third of patients with previously treated RAS-mutated PDAC; antitumor activity was also reported." 😑

Fucken market manipulators, smdh. Just let Black-Scholes-Merton function naturally.